prothrombotic
[용어속성] abnormalities
Prevalence of thrombosis in patients with cancer and SARS-CoV-2 infection
Article
[키워드] active cancer
added
Admitted Patient
analyzed
association
both group
Cancer
cancer patient
Cohort
COVID-19
cumulative
cumulative incidence
detect
diagnosed
English
Factores de Riesgo
hospital
incidence
Incidencia acumulada
increased risk
Infection
medical record
Mortality
obesity
Patient
Patients with cancer
prothrombotic
risk factor
SARS-COV-2 infection
significant difference
Spain
Spanish
statistically significant
study groups
thrombosis
thrombotic
thrombotic event
Thrombotic events
Trombosis
y COVID-19
[DOI] 10.1016/j.medcli.2021.08.002 PMC 바로가기
[DOI] 10.1016/j.medcli.2021.08.002 PMC 바로가기
Brain dural arteriovenous fistulas in the COVID-19 Era: A warning and rationale for association
Research article
[키워드] age
Artery
association
average
Brain dural arteriovenous fistula
cardiovascular risk factors
cerebral
Cerebral venous thrombosis
Clinical features
Cohort
conducted
connection
correlation
COVID-19
COVID-19 infection
COVID-19 vaccine
diagnosed
dural sinus thrombosis
Hemorrhagic
incidence
increase in
interval
males
Neurovascular
not different
objective
Pathogenesis
pathogenic
Patient
post-COVID-19 vaccination
prevaccination
prothrombotic
radiological
raise
Research
Result
retrospective
risk factor
Sex
significant increase
significantly higher
thrombotic
treated
vaccination
Vaccine
Vaccines
Vascular
venous
Warning
with COVID-19
[DOI] 10.1016/j.clineuro.2022.107367 [Article Type] Research article
[DOI] 10.1016/j.clineuro.2022.107367 [Article Type] Research article
Lipoprotein(a) during COVID-19 hospitalization: Thrombosis, inflammation, and mortality
Research article
[키워드] 1.26
adjusted hazard ratio
Biomarker
C-reactive protein
Coronavirus disease 2019
COVID-19
COVID-19 hospitalization
COVID-19 patients
CRP
D-dimer
death
discharge
elevated
hazard ratio
hospital
hospital discharge
hypothese
Inflammation
Inflammatory biomarker
interleukin-6
Mortality
multivariable
outcome
Patient
procalcitonin
proinflammatory
prothrombotic
Result
SARS-CoV-2
survival
tested
thrombotic
university
vaccination
with COVID-19
[DOI] 10.1016/j.atherosclerosis.2022.07.015 [Article Type] Research article
[DOI] 10.1016/j.atherosclerosis.2022.07.015 [Article Type] Research article
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Clinical Trial
[키워드] 1:1
95% CI
acute COVID-19
adjusted relative risk
age
Anti-inflammatory effects
Antithrombotic
antiviral properties
assigned
assumption
Berlin
body temperature
clinically
Control
control group
COVID-19
criteria
death
Efficacy
eight
eligible
enoxaparin
event rates
foundation
futility
Germany
heparin
hospitalisation
independent
initial
intention-to-treat population
interim analysis
investigator-initiated
IQR
Johanna
major bleeding
major bleeding event
median age
multicentre
nine
not reduce
Older
older patient
Open-label
outcome
Outpatient
parallel-group
participant
phase 3 trial
Prevent
Primary outcome
Probability
prothrombotic
randomisation
randomised
Randomly
receive
Registered
reported
respiratory infection
respiratory symptom
risk
Safety Monitoring Board
Serious Adverse Event
Standard of care
statistical
Study design
study population
Switzerland
symptomatic
Thromboprophylaxis
Treatment
Trial
university
University of Zurich
was done
were recorded
with COVID-19
women
[DOI] 10.1016/S2352-3026(22)00175-2 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1016/S2352-3026(22)00175-2 PMC 바로가기 [Article Type] Clinical Trial
Serum homocysteine level in pediatric patients with COVID-19 and its correlation with the disease severity
소아 코로나19 환자의 혈청 호모시스테인 수치와 질병 중증도와의 상관관계
Article
[키워드] acute infection
Admission
adult COVID-19 patients
Adults
Alanine
Alanine transaminase
aspartate
Aspartate transaminase
Biomarker
Biomarkers
Blood urea nitrogen
children
children with COVID-19
Complication
conducted
Control
coronavirus disease
Coronavirus disease 2019
correlated
correlation
COVID-19
COVID-19 patient
cross-sectional
cross-sectional study
D-dimer
detect
disease severity
Embolism
enzyme
enzyme-linked immunosorbent
enzyme-linked immunosorbent assay
ferritin
fibrinogen
fibrinogen degradation product
fibrinogen degradation products
healthy control
homocysteine
homocysteine.
increase in
intensive care
interquartile range
Laboratory
median
nitrogen
parameter
patients
pediatric
Pediatric patient
Pediatric patients
pediatrics
positive correlation
prothrombin
Prothrombin time
prothrombotic
radiological
Radiological parameters
reported
risk
serum
severity
severity of COVID-19
speculation
statistically significant
subjects
syndrome
the disease
thrombosis
urea
was measured
with COVID-19
[DOI] 10.1002/ppul.25920 PMC 바로가기 [Article Type] Article
[DOI] 10.1002/ppul.25920 PMC 바로가기 [Article Type] Article
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium
COVID-19의 혈전 위험에 대한 현재 및 신규 바이오마커: 국제 COVID-19 혈전증 바이오마커 콜로키움의 합의 성명
Review
Published on
Journal: Nature reviews. Cardiology [Category] COVID19(2023년), MERS, SARS, 바이오마커, 임상, 치료기술, 치료법,
Journal: Nature reviews. Cardiology [Category] COVID19(2023년), MERS, SARS, 바이오마커, 임상, 치료기술, 치료법,
[키워드] Activation
aggregation
Biomarker
Biomarkers
Clinical use
Coagulation
Coagulopathy
Consensus
coronavirus disease
Coronavirus disease 2019
COVID-19
current
D-dimer
disease
disease severity
Elevation
elevations
Endothelial cell
excessive inflammation
fibrinogen
fibrinolysis
hypercoagulability
in-hospital mortality
Injury
Intervention
marker
pandemic
Patient
patients
Platelet
platelet activation
platelet aggregation
platform
Post-vaccine
predict
Prognosis
prothrombotic
recommendation
Research
risk
risk stratification
syndrome
thrombocytopenia
thromboembolic
Thromboembolic events
thrombosis
thrombotic
thrombotic and thromboembolic events
thrombotic risk
with COVID-19
[DOI] 10.1038/s41569-021-00665-7 PMC 바로가기 [Article Type] Review
[DOI] 10.1038/s41569-021-00665-7 PMC 바로가기 [Article Type] Review
Vitamin D Endocrine System and COVID-19: Treatment with Calcifediol
비타민 D 내분비계와 코로나19: 칼시페디올로 치료
Review
[키워드] 25OHD
25OHD deficiency
25OHD level
25OHD levels
acute respiratory distress
acute respiratory distress syndrome
addition
Admission
angiotensin
antimicrobial peptides
Antiviral
Antiviral agents
approved
ARDS
association
autophagy
bradykinin
calcifediol
calcitriol
Characteristics
chemokine
cholecalciferol
coagulability
complications
Course
Coverage
COVID-19
COVID-19 pandemic
Critical
death
described
develop
dose
doses
drug
early stage
early stages
Effect
effector mechanisms
Endocrine
endocrine system
ENhance
epithelial
Evidence
functional
High dose
Host
hyperinflammatory phase
ICU
ICU admission
include
increased coagulability
indication
Infection
integrity
intensive care
intensive care unit
intervention study
mechanical ventilation
modulating
mortality rate
neutrophil
Patient
patients with SARS-CoV-2
pharmacokinetic
pilot study
prohormone
prothrombotic
public health systems
RAAS
reactive
reduce
Renin
repositioning
respiratory distress
Respiratory distress syndrome
risk
SARS-CoV-2
SARS-COV-2 infection
serum
severe COVID-19
significantly
subsequent
syndrome
System
the disease
therapeutic options
Treatment
treatment of COVID-19
vaccination
variant
VDES
viral evolution
Vitamin
Vitamin D
vitamin D endocrine system
vitamin D endocrine system.
[DOI] 10.3390/nu14132716 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/nu14132716 PMC 바로가기 [Article Type] Review
COVID-19 Related Thrombotic Complications Experience Before and During Delta Wave.
Research article
[키워드] 95% CI
95% confidence interval
active malignancy
acute respiratory syndrome
African American
Analysis
analyzed
anticoagulation
association
body mass index
caused
Comorbidities
Complication
complications
Computed tomography
coronavirus
Coronavirus disease 2019
COVID-19
COVID-19 Delta variant
COVID-19 infection
Delta
delta variant
demographic characteristics
Diagnosis
disease
elevated
evidenced
experience
Factor
Gender
group
higher risk
highlight
hypercoagulable
immunosuppressed patient
increased risk
infected with COVID-19
information
Jypercoagulable state
less
marker
objective
Odds ratio
pathophysiology
Patient
patients
patients with COVID-19
positive
Positive test
Prevent
prothrombotic
reported
Result
retrospective
risk
risk factor
SARS-CoV-2
significantly
study cohort
subject
Thromboembolism
thrombosis
thrombotic
thrombotic complication
thrombotic event
Thrombotic events
vaccination
variants of concern
venous
was performed
Wave
with COVID-19
[DOI] 10.1016/j.jvs.2022.04.053 [Article Type] Research article
[DOI] 10.1016/j.jvs.2022.04.053 [Article Type] Research article
Antigens and Antibodies of the Antiphospholipid Syndrome as New Allies in the Pathogenesis of COVID-19 Coagulopathy
COVID-19 응고병증의 병인에서 새로운 동맹자로서의 항인지질 증후군의 항원 및 항체
Review
Published on
Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 진단,
Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 진단,
[키워드] age-matched control
Ally
antibody
Anticoagulant
Antigen
antiphospholipid antibodies
Antiphospholipid syndrome
assays
association
B2GP1 deficiency
carried
caused
changed
Coagulopathy
conducted
COVID-19
COVID-19 coagulopathy
COVID-19 complications
COVID-19 patients
criteria
deficiency
Elderly patient
greater
heterogeneous
mechanism
New
occur
Patient
performed
physiological functions
Population
predisposition
Prevalence
prothrombotic
reduced
reported
SARS-CoV2 infection
syndrome
the disease
thrombotic event
was measured
[DOI] 10.3390/ijms23094946 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/ijms23094946 PMC 바로가기 [Article Type] Review